SAN DIEGO, Oct. 30 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (Nasdaq: AMLN) today announced that Adrian Adams has been elected to
the company's Board of Directors effective immediately.
"We are very pleased to welcome Adrian to the Amylin Board," said
Daniel M. Bradbury, President and CEO of Amylin Pharmaceuticals. "His
international experience as a highly innovative, strategic business leader,
combined with a track record of building organizations and delivering
optimum results will enhance our Board's depth of experience."
Mr. Adams currently serves as President and CEO of Sepracor, Inc. Prior
to this he was President and Chief Executive Officer of Kos Pharmaceuticals
from 2002 until the acquisition of the company by Abbott Laboratories in
December 2006. Mr. Adams has over 30 years of experience in both specialty
and large pharmaceutical organizations that, in addition to Sepracor and
Kos, included careers with ICI, SmithKline Beecham and Novartis, and
involved work and product launches in most therapeutic areas. Mr. Adams has
a broad background encompassing research and development, sales,
international and national product marketing, business development and
extensive general management experience.
He is a graduate of Manchester University in the United Kingdom with a
Bachelor of Science degree.
In addition to serving on the Amylin Board, Mr. Adams is actively
involved as a board member of PhRMA (Pharmaceutical Research and
Manufacturer of America).
About Amylin
Amylin Pharmaceuticals, Inc. is a biopharmaceutical company committed
to improving lives through the discovery, development and commercialization
of innovative medicines. Amylin has developed and gained approval for two
first- in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate)
injection and BYETTA(R) (exenatide) injection. Amylin's research and
development activities leverage the company's expertise in metabolism to
develop potential therapies to treat diabetes and obesity. Amylin is
headquartered in San Diego, California with over 1,800 employees
nationwide. Further information on Amylin Pharmaceuticals is available at
http://www.amylin.com.
SOURCE Amylin Pharmaceuticals, Inc.
 back to top
Related links:
http://www.amylin.com/
CONTACT:
Alice Bahner Izzo, Executive Director,
Corporate Affairs of Amylin Pharmaceuticals, Inc.,
+1-858-552-2200
|
